Falsified Medicines: Technological Innovations and Global Collaboration

Authors

  • Tengiz Verulava Caucasus University Author

Keywords:

pharmaceutical supply chain, artificial intelligence (AI), drug authentication, regulatory frameworks, patient safety

Abstract

Co­un­ter­fe­it and fal­si­fi­ed me­di­ci­nes po­se a se­ri­o­us thre­at to pa­ti­ent sa­fety, pub­lic he­alth, and the glo­bal eco­nomy. The wi­des­pre­ad na­tu­re of this prob­lem is dri­ven by re­gu­la­tory gaps, vul­ne­ra­bi­li­ti­es in the supply cha­in, tec­hno­lo­gi­cal bar­ri­ers, and low pub­lic awa­re­ness. To ad­dress the­se chal­len­ges, tec­hno­lo­gi­cal so­lu­ti­ons such as bloc­kcha­in, ar­ti­fi­ci­al in­tel­li­gen­ce (AI), and the Inter­net of Things (IoT) are be­ing ac­ti­vely de­ve­lo­ped to en­han­ce the tra­ce­a­bi­lity and aut­hen­ti­ca­ti­on of me­di­ci­nes. At the sa­me ti­me, it is es­sen­ti­al to stren­gthen in­ter­na­ti­o­nal co­o­pe­ra­ti­on, es­tab­lish ef­fec­ti­ve re­gu­la­tory fra­me­works, ra­i­se pub­lic awa­re­ness, and in­cre­a­se the ac­co­un­ta­bi­lity of the phar­ma­ce­u­ti­cal sec­tor. Fu­tu­re stra­te­gi­es sho­uld fo­cus on pro­mo­ting tec­hno­lo­gi­cal in­no­va­ti­on, fos­te­ring glo­bal co­or­di­na­ti­on, and adop­ting in­clu­si­ve po­li­ci­es to en­su­re a sa­fe and re­li­ab­le phar­ma­ce­u­ti­cal supply cha­in. The jo­int ac­ti­ons of all sta­ke­hol­ders, in­clu­ding go­ver­nments, phar­ma­ce­u­ti­cal com­pa­ni­es, in­ter­na­ti­o­nal or­ga­ni­za­ti­ons, and con­su­mers, are cru­ci­al in ac­hi­e­ving this go­al.

Downloads

Download data is not yet available.

References

Attaran, A., Barry, D., Basheer, S., et al. 2012. „How to achieve international ac-tion on falsified and substandard medicines.“ BMJ, 345, e7381. https://doi. org/10.1136/bmj.e7381.

Bate, R., Jensen, P., Hess, K., Mooney, L., & Guzman, J. 2018. „Substandard and falsified medicines: Estimated burden on global public health.“ PLoS Medi-cine, 15(2), e1002585. https://doi.org/10.1371/journal.pmed.1002585.

European Medicines Agency. 2019. Falsified medicines directive: Overview and implementation. London: EMA.

Fadlallah, R., El-Jardali, F., Hemadi, N., Morsi, R. Z., & Bou-Karroum, L. 2019. „Strategies and interventions to strengthen pharmacovigilance systems: A systematic review.“ Frontiers in Pharmacology, 10, 1635. https://doi.org/10. 3389/fphar.2019.01635

Kelesidis, T., & Falagas, M. E. 2015. „Substandard/counterfeit antimicrobial drugs.“ Clinical Microbiology Reviews, 28(2), 443-464. https://doi.org/10. 1128/CMR.00072-14

Mackey, T. K., & Liang, B. A. 2013. „Global reach of direct-to-consumer drug information websites: A cross-sectional study.“ BMC Medicine, 11, 214. ht-tps://doi.org/10.1186/1741-7015-11-214.

Newton, P. N., Green, M. D., & Fernández, F. M. 2019. „Impact of counterfeit medicines on public health.“ Trends in Pharmacological Sciences, 40(9), 580-591. https://doi.org/10.1016/j.tips.2019.06.003.

Nayyar, G. M. L., Breman, J. G., Newton, P. N., & Herrington, J. 2012. „Poor-quality antimalarial drugs in Southeast Asia and sub-Saharan Africa.“ The Lancet Infectious Diseases, 12(6), 488-496. https://doi.org/10.1016/S1473-3099(12)70064-6.

Pisani, E., Hasnida, A., & Nugroho, A. 2017. „Fighting counterfeit medicines in Indonesia: A policy analysis.“ Health Policy and Planning, 32(3), 321-328. https://doi.org/10.1093/heapol/czw128.

World Health Organization. 2017. WHO Global Surveillance and Monitoring System for Substandard and Falsified Medical Products. Geneva: WHO.

Downloads

Published

2026-03-19

Issue

Section

Social Sciences

How to Cite

Falsified Medicines: Technological Innovations and Global Collaboration. (2026). Bulletin of Akaki Tsereteli State University, 2(26), 272-287. https://moambe.journals.atsu.edu.ge/index.php/moambe/article/view/301

Similar Articles

11-20 of 32

You may also start an advanced similarity search for this article.